Cambridge, United States
Alnylam Pharmaceuticals, founded in 2002, stands at the forefront of RNA interference (RNAi) therapeutics, pioneering a groundbreaking approach to treat diseases by "silencing" the genes that contribute to them. Headquartered in the United States, Alnylam has emerged as a leader in the biopharmaceutical industry, with a proven track record of innovations and global reach.
The company’s slogan, "SILENCE DISEASE. AMPLIFY LIFE.™", encapsulates its mission to revolutionize medicine. Since the approval of its first commercial and globally pioneering RNAi therapeutic in 2018, Alnylam has launched a total of six approved medicines. This trajectory showcases the company's robust R&D capabilities and commitment to extending its therapeutic portfolio to address both rare and widespread diseases.
Employing over 2,600 individuals worldwide, Alnylam fosters an inclusive and dynamic workplace, earning recognition from prestigious publications like The Boston Globe, Science Magazine, Fast Company, and LinkedIn for its innovative work culture. Recently, the company secured a substantial $575.00M Post IPO Debt investment, reflecting investor confidence and underscoring its significant growth potential.
